Workflow
ZACKS
icon
Search documents
F or FSS: Which Is the Better Value Stock Right Now?
ZACKS· 2026-02-16 17:40
Core Viewpoint - Investors are evaluating Ford Motor Company (F) and Federal Signal (FSS) to determine which stock offers better value opportunities at present [1] Valuation Metrics - Ford has a Zacks Rank of 1 (Strong Buy) while Federal Signal has a Zacks Rank of 2 (Buy), indicating that Ford's earnings estimate revisions are more favorable [3] - Ford's forward P/E ratio is 9.28, significantly lower than Federal Signal's forward P/E of 26.24, suggesting Ford may be undervalued [5] - The PEG ratio for Ford is 0.34, while Federal Signal's PEG ratio is 1.87, indicating Ford's expected earnings growth is more attractive relative to its price [5] - Ford's P/B ratio stands at 1.56 compared to Federal Signal's P/B of 5.54, further supporting Ford's valuation advantage [6] Earnings Outlook - Ford is experiencing an improving earnings outlook, which enhances its attractiveness in the Zacks Rank model [7]
CRRFY or WMMVY: Which Is the Better Value Stock Right Now?
ZACKS· 2026-02-16 17:40
Core Viewpoint - Carrefour SA (CRRFY) and Wal-Mart de Mexico SAB de CV (WMMVY) are both attractive options for value investors, but Carrefour appears to be the superior choice based on valuation metrics [1][7]. Valuation Metrics - CRRFY has a forward P/E ratio of 9.87, while WMMVY has a forward P/E of 19.08, indicating that Carrefour is potentially undervalued compared to Wal-Mart de Mexico [5]. - The PEG ratio for CRRFY is 1.80, suggesting a more favorable earnings growth expectation relative to its price, whereas WMMVY has a PEG ratio of 5.55, indicating less attractive growth prospects [5]. - CRRFY's P/B ratio is 1.11, which is significantly lower than WMMVY's P/B of 4.95, further supporting the notion that Carrefour is undervalued [6]. Earnings Outlook - Both companies currently hold a Zacks Rank of 2 (Buy), reflecting an improving earnings outlook due to positive analyst estimate revisions [3].
VIV or CHT: Which Is the Better Value Stock Right Now?
ZACKS· 2026-02-16 17:40
Core Insights - The article compares Telefonica Brasil (VIV) and Chunghwa (CHT) to determine which stock offers better value for investors [1] Group 1: Zacks Rank and Analyst Outlook - Telefonica Brasil has a Zacks Rank of 1 (Strong Buy), indicating a more favorable earnings estimate revision trend compared to Chunghwa, which has a Zacks Rank of 3 (Hold) [3] - The improving analyst outlook for VIV suggests a more positive sentiment among analysts [3] Group 2: Valuation Metrics - VIV has a forward P/E ratio of 19.00, while CHT has a higher forward P/E of 25.43, indicating that VIV may be undervalued relative to CHT [5] - The PEG ratio for VIV is 0.88, significantly lower than CHT's PEG ratio of 5.40, suggesting better growth prospects relative to its valuation for VIV [5] - VIV's P/B ratio is 2.03, compared to CHT's P/B of 2.54, further supporting the argument that VIV is a more attractive investment [6] Group 3: Value Grades - VIV has earned a Value grade of B, while CHT has a Value grade of D, indicating that VIV is perceived as a better value stock [6] - The combination of Zacks Rank and Style Scores suggests that VIV stands out as the preferable option for value investors at this time [6]
GLNCY vs. WPM: Which Stock Is the Better Value Option?
ZACKS· 2026-02-16 17:40
Investors interested in stocks from the Mining - Miscellaneous sector have probably already heard of Glencore PLC (GLNCY) and Wheaton Precious Metals Corp. (WPM) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimat ...
VEOEY vs. WM: Which Stock Should Value Investors Buy Now?
ZACKS· 2026-02-16 17:40
Investors looking for stocks in the Waste Removal Services sector might want to consider either Veolia Environnement SA (VEOEY) or Waste Management (WM) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with s ...
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
ZACKS· 2026-02-16 17:35
Core Insights - CareDx (CDNA) announced clinical validation data for AlloHeme, a blood-based monitoring test aimed at predicting relapses in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) post-allogeneic hematopoietic cell transplant (HCT) [1][4] Group 1: AlloHeme Test Details - AlloHeme utilizes next-generation sequencing and artificial intelligence to enhance sensitivity in detecting early relapse signals compared to traditional methods [2][4] - The ACROBAT clinical study demonstrated that AlloHeme achieved 85% sensitivity and 92% specificity, detecting relapses a median of 41 days earlier than standard clinical diagnosis [9][12] - The assay's performance metrics indicate a 95% negative predictive value and a 79% positive predictive value, with an area under the curve of 0.89 [11] Group 2: Commercialization and Market Strategy - CareDx plans to roll out AlloHeme in the U.S. starting with CLIA readiness in 2026, followed by commercialization in 2027 and expected payer coverage by 2028 [3][9] - The company aims to expand its Transplant+ strategy into cell therapy and hematologic oncology, addressing unmet needs in AML and MDS monitoring [3][6] - The integrated offering will combine diagnostics, digital tools, and patient support solutions tailored for the cell therapy ecosystem [4][7] Group 3: Market Performance and Growth Potential - Following the announcement, CDNA shares increased by 2.8%, with a 65.6% rise over the past six months, significantly outperforming the industry and S&P 500 [5] - The clinical validation of AlloHeme is seen as a significant growth catalyst, enhancing CareDx's position in the cell therapy and hematologic oncology markets [6][7] - The cell therapy market is projected to reach $9.13 billion by 2026, with a compound annual growth rate (CAGR) of 22.9% through 2034, driven by advancements in technology and increasing disease prevalence [14][15]
Factors You Need to Know Ahead of TechnipFMC's Q4 Earnings Release
ZACKS· 2026-02-16 17:35
Core Viewpoint - TechnipFMC plc (FTI) is set to announce its fourth-quarter fiscal 2025 results on February 19, with earnings estimated at 51 cents per share and revenues at $2.55 billion [1] Group 1: Recent Performance - In the last reported quarter, FTI achieved adjusted earnings of 75 cents per share, surpassing the Zacks Consensus Estimate of 65 cents, driven by strong performance in the Subsea segment [2] - FTI's revenues for the last quarter were $2.6 billion, exceeding the Zacks Consensus Estimate by 1.2% [2] - FTI has beaten the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 20.16% [3] Group 2: Fourth Quarter Expectations - The Zacks Consensus Estimate for fourth-quarter fiscal 2025 earnings has remained unchanged, indicating a 5.56% year-over-year decrease, while revenue estimates suggest a 7.58% increase from the previous year [3] - FTI's revenue is expected to improve due to strong contributions from the Subsea segment, which is projected to generate $2.2 billion, reflecting an 8.7% year-over-year increase [4][5] - The company holds a $16.8 billion backlog, which, along with the ongoing industrialization of its Subsea business, is expected to positively influence fourth-quarter earnings [6] Group 3: Cost Considerations - Rising costs may negatively impact FTI's bottom line, with total costs and expenses increasing by 8.8% in the last quarter, a trend expected to continue [7] - The increase in costs is attributed to the inflationary environment and a tight labor market [7] Group 4: Earnings Prediction - The model predicts an earnings beat for FTI, supported by a positive Earnings ESP of +1.61% and a Zacks Rank of 2 (Buy) [10][11]
eBay to Report Q4 Earnings: What's in the Cards for the Stock?
ZACKS· 2026-02-16 17:30
Key Takeaways eBay is set to report Q4 2025 results with revenues guided to $2.83-$2.89B.EBAY expects GMV of $20.5-$20.9B, aided by marketplace upgrades and key partnerships.eBay sees mid-20% non-GAAP margins, reflecting higher costs and strategic investments.eBay (EBAY) is scheduled to report its fourth-quarter 2025 results on Feb. 18, 2026.For the fourth quarter, eBay expects total revenues between $2.83 billion and $2.89 billion. On an FX-neutral basis, year-over-year revenue growth is anticipated to be ...
PPL to Release Q4 Earnings: Time to Buy, Hold or Sell the Stock?
ZACKS· 2026-02-16 17:30
Core Insights - PPL Corporation (PPL) is anticipated to report its fourth-quarter 2025 results on February 20, with earnings expected to rise by 23.53% year-over-year to 42 cents per share and revenues projected to increase by 5.76% to $2.34 billion [1][6]. Financial Estimates - The Zacks Consensus Estimate for PPL's earnings per share (EPS) for the current quarter is 0.42, with a range of estimates from 0.41 to 0.42 [2]. - For the next quarter, the EPS estimate is 0.61, with a high estimate of 0.63 and a low of 0.57 [2]. - The current year EPS estimate stands at 1.82, reflecting a year-over-year growth of 7.69%, while the next year is projected at 1.95, indicating a growth of 7.54% [2]. Earnings Surprise History - PPL has beaten the Zacks Consensus Estimate in two of the last four quarters, resulting in a negative average surprise of 1.02% [3]. Earnings Prediction Model - The current Earnings ESP for PPL is 0.00%, and it holds a Zacks Rank of 3 (Hold), indicating that the model does not predict an earnings beat this time [5]. Key Factors Influencing Q4 Results - PPL's performance is likely to benefit from ongoing cost reduction initiatives, energy efficiency programs, and increased demand from data centers in Pennsylvania and the private sector in Kentucky [8][9]. - The expected return on capital investment in the latter half of 2025 is also anticipated to contribute positively to fourth-quarter earnings [8]. Stock Performance - Over the past three months, PPL's stock has returned 2.8%, outperforming the industry growth of 1.7% [12]. - PPL is trading at a forward price-to-earnings ratio of 19.16X, which is higher than the industry average of 17.17X [13]. Return on Equity - PPL's trailing 12-month return on equity (ROE) is 9.08%, which is below the industry average of 10.7% [15]. Investment Considerations - PPL plans to invest $20 billion from 2025 to 2028, focusing on infrastructure construction across generation, transmission, and distribution assets, which is expected to enhance system reliability [16]. - The company operates in a favorable regulatory environment, with over 60% of its capital investment plan eligible for contemporaneous recovery, mitigating the impact of regulatory lag on earnings [17]. - PPL has implemented common design and operational standards across its utilities to improve service resilience and efficiency in meeting rising customer demand [18]. Summary - PPL Corporation is positioned to benefit from rising demand, cost savings initiatives, and infrastructure upgrades, with strong liquidity and ongoing grid modernization serving as key tailwinds [19].
Live Nation to Report Q4 Earnings: What's in the Offing for the Stock?
ZACKS· 2026-02-16 17:20
Core Insights - Live Nation Entertainment, Inc. (LYV) is set to report its fourth-quarter 2025 results on February 19, after market close [1] - The company's adjusted earnings per share (EPS) for the last reported quarter missed the Zacks Consensus Estimate by 39.7% and declined 56% year over year, while revenues missed the consensus mark by 0.6% but increased 11% year over year [1] Earnings Performance - LYV's earnings exceeded the consensus estimate in two of the last four quarters, while missing in the other two, with an average surprise of 13.5% [2] Earnings Estimates - The Zacks Consensus Estimate for the fourth-quarter loss has widened to $1.02 per share from a previous estimate of a loss of 97 cents, compared to an adjusted EPS of 56 cents in the same quarter last year [3] - Revenue estimates for the fourth quarter are projected at $6.07 billion, reflecting a 6.9% increase from $5.68 billion reported in the prior year [3] Revenue Drivers - The anticipated revenue growth in the fourth quarter is attributed to pent-up demand for live events and strong ticket sales, supported by high attendance at large venues and sustained international demand [4] - Concert revenues are expected to rise by 7.5% year over year to $4.9 billion, while Sponsorship and Advertising revenues are projected to increase by 15.2% to $324 million, and Ticketing revenues by 4.2% to $876.2 million [5] Cost Pressures - Increased labor-hiring costs, artist activation costs, and other operational expenses are likely to negatively impact LYV's bottom line for the quarter [6] - The company is also facing rising venue costs and service fees, with caution regarding cost overruns related to the development and expansion of live music venues [6] Earnings Prediction Model - The current model does not predict an earnings beat for Live Nation Entertainment, as it has an Earnings ESP of -15.45% and a Zacks Rank of 5 (Strong Sell) [7][8]